Case Report: Malignant melanoma in a patient with Crohn’s disease treated with ustekinumab [version 2; peer review: 2 approved]

Case Report: Malignant melanoma in a patient with Crohn’s disease treated with ustekinumab [version 2; peer review: 2 approved]

The cornerstone of inflammatory bowel disease (IBD) treatment is immunomodulators. IBD patients are at increased risk of intestinal and extraintestinal malignancy. Ustekinumab is a fully humanized monoclonal anti-IL12/23 antibody with a good safety profile. Malignancies of breast, colon, head and ne...

Full description

Bibliographic Details
Main Authors: Georgios Axiaris, Leonidas Marinos, Marina Papoutsaki, Alexandros Ioannou, Spyridon Michopoulos, Michael Liontos, Evanthia Zampeli
Format: Article
Language:English
Published: F1000 Research Ltd 2023-10-01
Series:F1000Research
Subjects:
Melanoma
IBD
Crohn’s disease
Ustekinumab
eng
Online Access:https://f1000research.com/articles/11-424/v2

Internet

https://f1000research.com/articles/11-424/v2

Similar Items